XILIO THERAPEUTICS Trademark

Trademark Overview

On Monday, February 3, 2020, a trademark application was filed for XILIO THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the XILIO THERAPEUTICS trademark a serial number of 88981516. The federal status of this trademark filing is REGISTERED as of Tuesday, July 13, 2021. This trademark is owned by Akrevia Therapeutics, Inc.. The XILIO THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer, all of the foregoing excluding research and development services for pharmaceutical products for sleep disorders, central nervous disorders (other than cancers of the central nervous system), and neurological disorders (other than cancers of the neurological system)
xilio therapeutics

General Information

Serial Number88981516
Word MarkXILIO THERAPEUTICS
Filing DateMonday, February 3, 2020
Status700 - REGISTERED
Status DateTuesday, July 13, 2021
Registration Number6421510
Registration DateTuesday, July 13, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 2, 2020

Trademark Statements

Disclaimer with Predetermined Text"THERAPEUTICS"
Goods and ServicesPharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer, all of the foregoing excluding research and development services for pharmaceutical products for sleep disorders, central nervous disorders (other than cancers of the central nervous system), and neurological disorders (other than cancers of the neurological system)

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, February 7, 2020
Primary Code042
First Use Anywhere DateTuesday, March 2, 2021
First Use In Commerce DateTuesday, March 2, 2021

Trademark Owner History

Party NameXILIO DEVELOPMENT, INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02139
Party NameXILIO DEVELOPMENT, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02139
Party NameAkrevia Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameAkrevia Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Tuesday, February 27, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, February 27, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 27, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 13, 2021REGISTERED-PRINCIPAL REGISTER
Thursday, June 10, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, June 9, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, May 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 3, 2021STATEMENT OF USE PROCESSING COMPLETE
Tuesday, April 6, 2021USE AMENDMENT FILED
Tuesday, April 6, 2021SOU EXTENSION 1 GRANTED
Tuesday, April 6, 2021SOU EXTENSION 1 FILED
Monday, May 3, 2021DIVISIONAL PROCESSING COMPLETE
Tuesday, April 6, 2021DIVISIONAL REQUEST RECEIVED
Monday, April 26, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, April 6, 2021TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, April 6, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, April 6, 2021TEAS STATEMENT OF USE RECEIVED
Tuesday, December 8, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 25, 2020ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, October 28, 2020CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Tuesday, October 27, 2020ASSIGNED TO PETITION STAFF
Wednesday, October 14, 2020AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sunday, October 11, 2020EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, September 16, 2020TEAS POST PUBLICATION AMENDMENT RECEIVED
Monday, June 29, 2020EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, June 2, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 2, 2020PUBLISHED FOR OPPOSITION
Wednesday, May 13, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, April 24, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 22, 2020ASSIGNED TO EXAMINER
Friday, February 7, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 6, 2020NEW APPLICATION ENTERED

Related Keywords

therapeutics xilio development research disorders nervous central other pharmaceutical cancers neurological system